Skip to main content

Year: 2023

Edible Garden Available at Tops Friendly Markets; Expands Company’s Distribution Network in New York, Pennsylvania, and Vermont

BELVIDERE, NJ, Oct. 30, 2023 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that Tops Friendly Markets, a subsidiary of Northeast Grocery, will begin carrying Edible Garden’s products in all of their locations across New York, Pennsylvania and Vermont. Mr. Jim Kras, Chief Executive Officer of Edible Garden, stated, “We are pleased to announce that Tops Friendly Markets will now feature our sustainable herbs throughout their 149 retail locations in New York, Pennsylvania, and Vermont. Their addition to our already robust distribution network enhances the Company’s presence in the Northeastern United States. Our track record, marked by...

Continue reading

Augmedix to Announce Third Quarter 2023 Financial Results and Host Investor Conference Call on November 6, 2023

SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) — Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today it will report financial results for the third quarter ended September 30, 2023, on Monday, November 6, 2023, after the market closes. Management will host a conference call that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the conference call will be available on the “Events” section of the Company’s website at: https://ir.augmedix.com/news-events. Alternatively, interested parties can dial 877-407-3982 (toll-free) or 201-493-6780 (international) to listen. The webcast will be archived and available for replay after the event. About Augmedix Augmedix (Nasdaq: AUGX) delivers industry-leading, ambient medical...

Continue reading

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b clinical trial in the first half of 2024BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive...

Continue reading

Colliers named on Forbes list of World’s Best Employers 2023

TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) — Global professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) has been named by Forbes on the 2023 list of World’s Best Employers. Colliers also ranked among the top 10 professional services companies and was the only global, full-service commercial real estate firm to receive this prestigious global employer accolade. In its seventh year, the Forbes list is based on an independent survey of 170,000 full-time and part-time workers from 55 countries working for multinational companies and institutions. Respondents were asked whether they would recommend their company to others, to rate their employers on facets such as talent development, gender equality, and social responsibility, and make recommendations about employers in sectors or industries besides their...

Continue reading

Blue Water Biotech Issues Letter to Shareholders

CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (Nasdaq: BWV) (“BWB” or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer Dr. Neil Campbell. Dear Shareholders, As we close out October and the first month under my tenure, I want to take this opportunity to personally communicate with you while providing an update on the direction of Blue Water Biotech. 2023 has been an eventful year that has significantly influenced the Company’s progression in generating shareholder value. On October 24, 2023, Blue Water Biotech received a letter from Nasdaq informing the Company that it is back in compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1). This completes our outstanding obligations to the Nasdaq, and we will work diligently moving...

Continue reading

Enthusiast Gaming to Announce Third Quarter 2023 Results on November 13, 2023

LOS ANGELES, Oct. 30, 2023 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ:EGLX; TSX:EGLX) will report financial and operating results for its third quarter ending September 30, 2023, on Monday, November 13, 2023, after the market closes. Management will host a conference call and webcast that same day at 5:00 p.m. ET. Conference call details: Toll Free: 1-855-239-1101 (Conference ID: 10183500) Live Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1639210&tp_key=0dd483b8ce An archived recording of the webcast will be available on the Investor Relations page of the Enthusiast Gaming website, enthusiastgaming.com/investors. About Enthusiast Gaming Enthusiast Gaming is the leading gaming media and entertainment company in North America, building the largest platform for...

Continue reading

Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) — Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coating immune protection technology program, that is used in combination with the Cell Pouch™. The goal of the program is to eliminate the need for chronic immunosuppression medications, currently used in islet cell transplantation for type 1 diabetes (T1D) treatment. The update was presented by Dr. Alice Tomei, of the University of Miami, at the International Pancreas and Islet Transplant Association (IPITA)-International Xenotransplantation Association (IXA)-Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress, taking place from October 26-29 in San Diego, California. The...

Continue reading

New Time for the Stellantis Third Quarter 2023 Shipments and Revenues on October 31

 New Time for the Stellantis Third Quarter 2023Shipments and Revenues on October 31 AMSTERDAM, October 30, 2023 – Stellantis N.V. announced today a new time for its Third Quarter 2023 Shipments and Revenues on Tuesday, October 31, 2023. A live audio webcast and conference call of the Third Quarter 2023 Shipments and Revenues will begin at 2:00 p.m. CET / 9:00 a.m. EDT on Tuesday, October 31, 2023. The related press release and presentation material are expected to be posted under the Investors section of the Stellantis corporate website at www.stellantis.com at approximately 8:00 a.m. CET / 3:00 a.m. EDT on Tuesday, October 31, 2023. Details for accessing this presentation are available under the Investors section of the Stellantis corporate website at www.stellantis.com. For those unable to participate in the live session, a recorded...

Continue reading

Ero Copper Agrees with Vale Base Metals to Enter into Earn-in Agreement for a 60% Interest in the Furnas Copper Project

(all amounts in US dollars, unless otherwise noted)Figure 1Map of the Carajás Mineral Province, highlighting the location of Furnas as well as the Tucumã Project.Figure 2Furnas Plan View Map, including drill collar locations.Figure 3Cross section within the high-grade SE Zone of Furnas.Figure 4Cross section within the high-grade NW Zone of Furnas.VANCOUVER, British Columbia, Oct. 30, 2023 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to announce it has entered into a binding term sheet (“Term Sheet”) with Salobo Metais S.A, part of the Vale Base Metals business (“VBM”) to advance its Furnas copper project (“Furnas” or the “Project”) located in the Carajás Mineral Province in Pará State,...

Continue reading

Check Point Software Reports 2023 Third Quarter Financial Results

SAN CARLOS, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the third quarter ended September 30, 2023. Third Quarter 2023:                                                         Total Revenues: $596 million, a 3 percent increase year over year Security Subscriptions Revenues: $248 million, a 15 percent increase year over year Deferred Revenues: $1,709 million, a 4 percent increase year over year GAAP Operating Income: $226 million, representing 38 percent of revenues Non-GAAP Operating Income: $269 million, representing 45 percent of revenues GAAP EPS: $1.75, a 19 percent increase year over year Non-GAAP EPS: $2.07, a 17 percent increase year over year“Our third quarter performance was strong, marked by a 17 percent increase in earnings...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.